Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "acromegaly" wg kryterium: Temat


Wyświetlanie 1-5 z 5
Tytuł:
Screening colonoscopy tests in acromegaly patients – authors’ observations
Autorzy:
Malicka, Joanna
Kurowska, Maria
Dudzińska, Marta
Smoleń, Agata
Oszywa-Chabros, Anna
Tarach, Jerzy
Powiązania:
https://bibliotekanauki.pl/articles/552976.pdf
Data publikacji:
2016
Wydawca:
Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
Tematy:
acromegaly
colonoscopy
colon neoplasm.
Źródło:
Family Medicine & Primary Care Review; 2016, 3; 286-290
1734-3402
Pojawia się w:
Family Medicine & Primary Care Review
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Disorders of carbohydrate metabolism and their relationship with the prevalence of cancer in patients with acromegaly – authors’ own observations
Autorzy:
Malicka, Joanna
Kurowska, Maria
Dudzińska, Marta
Smoleń, Agata
Oszywa-Chabros, Anna
Tarach, Jerzy
Powiązania:
https://bibliotekanauki.pl/articles/553129.pdf
Data publikacji:
2016
Wydawca:
Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
Tematy:
acromegaly
diabetes
prediabetes
malignancy.
Źródło:
Family Medicine & Primary Care Review; 2016, 3; 291-293
1734-3402
Pojawia się w:
Family Medicine & Primary Care Review
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Prevalence of neoplasms in patients with acromegaly – the need for a national registry
Autorzy:
Matyjaszek-Matuszek, B.
Obel, E.
Lewicki, M.
Kowalczyk-Bołtuć, J.
Smoleń, A.
Powiązania:
https://bibliotekanauki.pl/articles/2081765.pdf
Data publikacji:
2018
Wydawca:
Instytut Medycyny Wsi
Tematy:
cancer
acromegaly
registry
IGF-1
GH
neoplasms
Opis:
Introduction. Acromegaly is an endocrine disorder caused predominantly by pituitary adenoma leading to autonomic oversecretion of growth hormone and secondary elevation of insulin-like growth factor 1 (IGF-1). Consequently, there are both theoretical and experimental grounds for establishing a correlation between this disorder and the higher incidence of neoplasms. Objective. The aim of the study is to evaluate the incidence and types of neoplasms among patients with acromegaly. Materials and method. The study included 67 patients with acromegaly, aged between 24 and 75±18.8 years, 46 women (68.7%) and 21 men (31.3%), BMI: 30.7±5.7 kg/m2, age at diagnosis 49.1±12.5 years, with the medians of GH and IGF-1 levels at diagnosis of 11.3 ng/ml and 663.8 ng/ml, respectively. A retrospective analysis of medical records with particular regard to physical examination, medical history, laboratory and imaging tests was performed. Results. Fifty-one patients (76.1%) suffered from at least one neoplasm, among whom 48 patients (71.6%) had benign proliferations, whereas malignant neoplasms (larynx, endometrial and colon cancers) were found in only three patients (4.5%). Conclusions. Benign neoplasms were found in majority of patients with acromegaly (71.6%) most notably: nodular goiter and colon polyps; malignant lesions were rare (4.5%). Only every fifth patient suffered from no neoplastic proliferations. No correlations between the studied parameters and the incidence of neoplasms were found, most likely due to the small number of patients. This is the reason for proposing the creating of the first national register of incidences of neoplasms among acromegalic patients.
Źródło:
Annals of Agricultural and Environmental Medicine; 2018, 25, 3; 559-561
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Long-standing acromegaly in a patient with a pituitary adenoma not visible on MRI
Autorzy:
Kurowska, Maria
Malicka, Joanna
Tarach, Jerzy S.
Powiązania:
https://bibliotekanauki.pl/articles/1061851.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
acromegaly
ectopic GHRH secretion
microadenoma
neuroendocrine tumour
Opis:
Introduction: Acromegaly in the course of a pituitary microadenoma or neuroendocrine GHRH-secreting tumour (GHRH, growth hormone-releasing hormone) invisible on MRI is very rare. Objective: To present the difficulties in determining the cause behind an excessive production of the growth hormone in a patient suffering from long-standing acromegaly, without a pituitary focal lesion that would be visible on MRI. Case report: The authors describe a case of a 69-year-old female with acromegaly, diagnosed 22 years earlier based on the typical somatic symptoms, and confirmed by the elevated concentration of insulin- like growth factor type 1 and lack of growth hormone suppression in the oral glucose tolerance test. The initial MRI scan (1994) had revealed a hypoechogenic 2 x 3 mm lesion in the anterior lobe of the pituitary gland, whose presence was not reported in the subsequent MRI tests. As ectopic GHRH or growth hormone secretion was suspected, a neuroendocrine tumour was searched for. The 47.7 × 54 × 35.7 mm tumour, located in the thoracic outlet, accumulating tektreotide in receptor scintigraphy, turned out to be a nodular goitre on histopathology. Due to the undetermined location of the source of growth hormone overproduction, failure to measure GHRH levels, and the patient’s lack of consent to undergo sella turcica exploration, long-acting release octreotide had been used for many years to manage the patient’s condition. Conclusion: The long-lasting and ineffective search for a neuroendocrine tumour producing GHRH or growth hormone as well as the absence of a focal lesion in the repeated MRI scans render it impossible to unequivocally determine the cause of the patient’s acromegaly, and illustrate the difficulties in discovering the source of growth hormone overproduction.
Źródło:
OncoReview; 2017, 7, 1; 32-37
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Autorzy:
Witek, Przemysław
Gutowska, Marta
Powiązania:
https://bibliotekanauki.pl/articles/1064786.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
acromegaly
growth hormone
insulin-like growth factor 1
lanreotide
long-acting somatostatin analogues
octreotide
pasireotide
somatotroph pituitary adenoma
tumour volume reduction
Opis:
Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth factor 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery. The long-acting somatostatin analogues reduce serum GH/IGF-1 levels and tumour volume. In this clinical review, mechanisms and role of 1st and 2nd generation somatostatin analogues in the treatment of patients with acromegaly are presented, with particular emphasis on the effects on somatotroph pituitary adenoma volume reduction.
Źródło:
OncoReview; 2016, 6, 4; A162-168
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies